

19th Meeting of the **EUROPEAN ASSOCIATION** FOR CANCER RESEARCH

# **Budapest, Hungary** 1-4 July 2006

## **Advance Programme Call for Abstracts**







Organised under the auspices of the Federation of European Cancer Societies www.fecs.be

**Under the patronage of**Professor E. Sylvester Vizi,
President of the Hungarian Academy of Sciences

Dear colleagues and friends,

I am delighted to welcome you all to EACR-19 in the beautiful city of Budapest, and hope that you will find inspiration in the setting and in the science - the best of basic and translational cancer research in Europe. The scientific programme committee has worked hard to ensure that all aspects of current molecular biology, cell biology, immunology and genetics are well represented. In addition, we have a number of key-note speakers who will describe the growing success of transferring basic research into effective, low toxicity targeted therapies. It is the most exciting time to be working in this field as we now see real examples of how the investment in basic and clinical research is being manifest in new treatments. There are many challenges ahead but the prospect is one of great optimism.

The European Association for Cancer Research was established in 1968 to support and facilitate the work of basic cancer researchers in Europe. We have seen many changes in our professions over that time and in my experience one of the most rewarding aspects of this work is that we have had to constantly adapt and learn. EACR are also conscious of evolving our meetings to ensure that those who attend gain the most from them and I hope that we shall also be able to broadcast some of the sessions on the web.

I am very grateful to all of those who have contributed their time and effort in both organising this meeting and in participating. In particular I extend my thanks to the FECS Conference team and to Professor Edith Oláh, Chair of the Local Organising Committee. I cannot finish without mentioning our own tremendously efficient office staff, Paul Saunders and Kathryn Wass, who make my job such a pleasant one.

Enjoy the meeting and then go home inspired to do even better work!

Prof. W.J. Gullick
President of the EACR
Conference and Scientific Chairman

#### Conference venue

The 19th EACR meeting will take place in:

Novotel Budapest Congress Centre H-1123 Budapest, Jagellò ùt 1-3

Budapest is a very beautiful and romantic city, embracing the river Danube. It is illuminated with historical buildings which abound in art and architectural treasures. The city resonates with the sounds of classical and traditional light music and plays host to numerous cultural events.

#### Useful on-line links:

www.bcc.hu www.hungarytourism.hu www.malev.hu

## **Important dates**

6 January 2006	Abstract submission open
3 February 2006	Deadline payment for early registration
10 March 2006	Deadline abstract submission
19 May 2006	Deadline hotel reservation
16 June 2006	Deadline payment for late registration (closure pre-registration)
After 16 June 2006	On-site registration only

## **Conference secretariat**





#### For further details please contact:

EACR-19 Secretariat Federation of European Cancer Societies Avenue E. Mounier 83 B-1200 Brussels Belgium

Telephone: +32 (0)2 775 02 01 Fax: +32 (0)2 775 02 00 E-mail: EACR19@fecs.be

www.fecs.be

## **CONFERENCE COMMITTEES**

## **Organising Committee**

W.J. Gullick, Conference and Scientific Chair

H. Grunicke

R. Marais

E. Oláh, Local Organiser

M. Pierotti

P. Saunders

K. Schlaefer

#### Scientific Programme Committee

W.J. Gullick, Scientific Programme Committee Chair

P. Boffetta

J. Celis

M.P. Colombo

J. Downward

S. A. Eccles

A. Gescher

H. Grunicke

E. Oláh

R. Perona

M. Pierotti

M.A. Piris

Y. Yarden

## Young Cancer Researchers Committee

R.J. White, Chair

J. Downs

V. Jendrossek

R. Marais

T. Sørlie

## **Local Organising Committee**

E. Oláh, Chair

R. Ádány

M. Kásler

J. Tímár

A. Tompa

## **S**CIENTIFIC PROGRAMME OVERVIEW

	Saturday 1	July 2006		Sunday 2	July 2006
			8.00	Education	al Lecture
				Signal transduction network	Gene expression profiling
			9.00	Plenary	Lecture
				Europe aga	inst cancer
			9.45	Coffee	break
			10.15	Sympo	osium
				Molecular determinants of site specific metastasis	Canceromics
			12.15	Lur	nch
13.00	Opening (	Ceremony	12.30	Satellite Symposium	Workshop
13.30	Mühlboc	k Lecture	13.45	Award	Lecture
	The control of DNA exploitation for cancer	replication and its diagnosis or treatment		Anthony Dipple Carcino	ogenesis Award Lecture
14.30	Coffee	break	14.35	Presidenti	al Session
15.00	Symp	osium			
	Cancer cell growth	Genetics and the environment	16.05	Poster sessions	s/Coffee break
17.00	Rece	otion	18.00	Plenary	Lecture
				Angiog	enesis
			19.00	General A	Assembly

	Monday 3	July 2006		Tuesday 4	July 2006
8.00	Educational Lecture		8.00	Educational Lecture	
	Proteomics/mass spectrometry	Radiation oncology		Dynamic imaging of cell invasion	Bioinformatics
9.00	Plenary	Lecture	9.00	Plenary Lecture	
	p53 and	l cancer		Systems biology	
9.45	Coffee	break	9.45	Coffee	break
10.15	Sympo	osium	10.15	Presidenti	al Session
	Experimental therapeutics	Cancer stem cells			
12.15	Lur	nch	11.45	Poster sess	ions/Lunch
12.30	Satellite Symposium	Workshop			
13.45	Award Lecture		13.45	Award	Lecture
	EACR Young Cancer Researcher's Award Lecture			Carcinogenesis Young Inv	estigator's Award Lecture
14.35	Sympo	osium	14.30	Mike Pric	e Lecture
	Inflammation and cancer	Cancer epigenetics		Targeted	therapies
16.05	Poster session:	s/Coffee break	15.30	Closing C	eremony
18.00	Plenary	Lecture			
	Identification of car using functional g				
20.00	Conference Dinner				

## **S**CIENTIFIC PROGRAMME

#### Saturday 1 July 2006

#### 13:30-14:30 Mühlbock Lecture

The control of DNA replication and its exploitation for cancer diagnosis or treatment

Chair W.J. Gullick (UK) Speaker R. Laskey (UK)

#### 15:00-17:00 Symposium

#### Cancer cell growth

Chair R.J. White (UK)

- The role of RNA polymerase III transcription in cell growth and cancer *R.J. White (UK)*
- How TOR signalling controls cell growth M.N. Hall (CH)
- Does the ribsome translate cancer? P.P. Pandolfi (USA)
- The role of RNA polymerase I transcription in cell growth and cancer R.D. Hannan (AUS)

#### 15:00-17:00 Symposium

#### Genetics and the environment

Chair P. Boffetta (F)

- Whole genome scans: lessons from the analysis of breast cancer susceptibility *TBA*
- What linkage analysis can still tell us D. Goldgar (USA)
- The search for gene-environment interactions: association studies in Central Europe *P. Brennan (F)*
- The importance of non-genetic causes of cancer – P. Boffetta (F)

## Sunday 2 July 2006

08:00-09:00 Educational Lecture

Signal transduction network

Speaker Y. Yarden (IL)

08:00-09:00 Educational Lecture

Gene expression profiling

Speaker T. Sørlie (NO)

09:00-09:45 Plenary Lecture

**Europe against cancer** 

Chair E. Oláh (HU) Speaker P. Boyle (F)

10:15-12:15 Symposium

Molecular determintants of site specific metastasis

Chair S.A. Eccles (UK)

- Molecular determinants of site specific metastasis TBA
- Bone metastasis A. Teti (CH)
- HDACS and angiogenesis V. Castronovo (B)
- Lymphatic metastasis K. Alitalo, (FIN)

10:15-12:15 Symposium

**Canceromics** 

Chair T. Sørlie (NO)

- The cancer kinome A. Bardelli, (IT)
- □ Cancer cell genome *M. Stratton*
- Proteomic analysis for the early detection of cancer
   E.C Kohn (USA)
- Omics approach to cancer- microchips technologies
   O. Kallioniemi (FIN)

## SCIENTIFIC PROGRAMME

13:45-14:30	The Anthony Dipple Carcinogenesis Award Lecture		
	To be announced		
14:35-16:05	Presidential Session		
	The best proffered papers will be presented.		
16:05-18:00	Poster Sessions		
18:00-18:45	Plenary Lecture		
	Angiogenesis		
	Chair H. Grunicke (AT) Speaker W.G. Kaelin, Jr (USA)		
	Monday 3 July 2006		
08:00-09:00	Educational Lecture		
	Proteomics and mass spectrometry		
	Speaker M. Smales (UK)		
08:00-09:00	Educational Lecture		
	Radiation oncology		
	Speaker C. Belka (DE)		
09:00-09:45	Plenary Lecture		
	p53 and cancer		
	Chair R. Marais (UK) Speaker K. Vousden (UK)		
10:15-12:15	Symposium		
	Experimental therapeutics		
	Chair J.C. Lacal (ES)		
	Therapeutic approaches to target raf signalling in cancer		
	■ PI3K/mTOR pathway as therapeutic targets – G. Mills (USA)		
	<ul> <li>Preclinical and clinical studies of Hsp90 inhibitors</li> <li>P. Workman (LIK)</li> </ul>		
	Choline kinase in human cacinogenesis – J.C. Lacal (ES)		
09:00-09:45	Radiation oncology  Speaker C. Belka (DE)  Plenary Lecture  p53 and cancer  Chair R. Marais (UK) Speaker K. Vousden (UK)  Symposium  Experimental therapeutics  Chair J.C. Lacal (ES)  Therapeutic approaches to target raf signalling in cancer  - R. Marais (UK)  PI3K/mTOR pathway as therapeutic targets – G. Mills (USA)  Preclinical and clinical studies of Hsp90 inhibitors  - P. Workman (UK)		

10:15-12:15 Symposium

Cancer stem cells

Chair H. Clevers (NL)

To be announced

13:45-14:30 EACR Young Cancer Researcher's Award Lecture

To be announced

14:35-16:05 Symposium

Inflammation and cancer

Chair M.P. Colombo (IT)

- Pathogens induced chronic inflammation and cancer
   M. Naumann (DE)
- NF-kappaB in inflammation- associated cancer
   E. Pikarski (IL)
- Immune Cells promoting cancer development
   L.M. Coussens (USA)
- Macrophage produced extracellular matrix in cancer development – M.P. Colombo (IT)

14:35-16:05 Symposium

**Cancer epigenetics** 

Chair J. Downs (UK)

- Methyl CpG binding proteins and cancer TBA
- Epigenetic regulation by DNA methylation of tumour suppressor genes – P. Jones (USA)
- Chromatin regulation during proliferation and differentiation
   A. Brehm (DE)
- Epigenetic marks in chromatin/identification of chromatin modifying enzymes by bioinformatics – R. Aasland (NO)

16:05-18:00 Poster Sessions

18:00-18:45 Plenary Lecture

Identification of cancer relevant genes using functional genetic approaches

Chair J. Celis (DK) Speaker R. Bernards (NL)

#### SCIENTIFIC PROGRAMME

	Tuesday 4 July 2006		
08:00-09:00	Educational Lecture		
	Dynamic imaging of cell invasion in vitro an in vivo		
	Speaker P. Friedl (DE)		
08:00-09:00	Educational Lecture		
	Bioinformatics		
	Speaker A. Brazma (UK)		
09:00-09:45	Plenary Lecture		
	Systems biology		
	Chair V. Jendrossek (DE)		
	Speaker J.W. Gray (USA)		
10.15-11.45	Presidential Session		
	The best proffered papers will be presented.		
11:45-13:45	Poster Sessions		
13:45-14:30	Carcinogenesis Young Investigator's Award Lecture		
	To be announced		
14:30-15:30	Mike Price Lecture		
	Targeted therapy		
	Chair M. Pierotti (IT) Speaker J. Baselga (ES)		

## Young Cancer Researcher's Workshops

These workshops have been organised for young investigators (postgraduate students, 1st year postdoctoral scientists... etc), who would like to be informed about the various paths for career progression. Three workshops will be organised, these are:

## How to be effective in applying for fellowships

This workshop will discuss applying for fellowships at a national level and a European level. The participants will be informed on how to write effective applications and the pitfalls to avoid.

## Introduction to pharmaceutical research and development

This workshop will discuss the processes that Industry uses when developing drugs for diseases. It is particularly of interest to young investigators who would like to embark in a career in pharmaceutical R & D.

The main topics that will be covered are:

- What is a drug target?
- How are leads generated?
- Concept testing
- Undertaking clinical trials

## From PhD student to group leader

This workshop will discuss the steps that a newly qualified postdoctoral scientist can take to further his/her career, such as the number of postdoctoral positions that he/she should take before becoming a group leader and running one's own group. Representatives from two European countries will discuss the differences between a career in an university environment and a career in a research institute.

#### CALL FOR ABSTRACTS

#### **Abstract submission procedure**

#### Abstract submission deadline: 10 March 2006

Abstracts must be submitted on-line via the FECS website: www.fecs.be

Abstracts can be submitted as of 6 January 2006.

Abstracts sent by post, fax or e-mail will NOT be accepted.

The presenting author of an accepted abstract will be allowed to register at the early rate. This special registration is only open for ONE week in May 2006.

## **Abstract regulations**

With the submission of an abstract to EACR-19, the first author (presenting author):

- Accepts responsibility for the accuracy of the submitted abstract.
- Confirms that all authors are aware of and agree to the content of the abstract and support the data presented.
- Warrants that the data and conclusions presented in the abstract have not been published in the same format and with the same title prior to the date of the conference.
- Identifies any financial interest in products or processes described in the abstract. This information is to be forwarded to the Scientific Committee together with the abstract.
- States that, for studies involving human or animal subjects, permission has been obtained from the relevant regulatory authority and properly informed consent given where appropriate.
- Gives permission for the abstract, when selected for presentation (oral or poster), to be published. Submitted abstracts cannot be withdrawn after 17 March 2006

#### **Abstract format**

In order to be considered, an abstract should respect the following guidelines:

 The abstract must be submitted in good English. The Scientific Committee reserves the right to reject those abstracts, which are presented in poor English, or may request an immediate revision by the presenter.

- The title of the abstract should be brief and reflect the content
  of the abstract. Do not use capital letters in the title except
  for words that are always capitalised and do not use nonstandard abbreviations. Commercial names may not be used
  in the abstract title.
- No more than 10 authors can be listed. Only institutional affiliations, cities and countries should follow.
- Abstracts should be structured in such a way as to include:
  - an introductory sentence indicating the purpose of the study
  - 2. a brief description of pertinent experimental procedures
  - 3. a summary of the results of the research
  - 4. the main conclusions
- The on-line abstract submission procedure will not accept abstracts that exceed 2 500 characters (body of the abstract).
- Abbreviations may be used if standard or if spelled out and defined at the first use. Compounds should be mentioned with the generic name, in lower case. Commercial names are permitted in the text, with an ®, and if in brackets following the generic name, i.e. "generic (Commercial ®)".
- Supplementary data or appendices will not be accepted.
- Figures or photographs are not allowed. Symbols and structures of drugs are allowed and should be drawn in black.

## **Abstract selection process**

The Scientific Committee will make the selection of abstracts for oral and poster presentations in April 2006. By May 2006, the first author (presenter) will receive an e-mail with the result of the review and the Scientific Committee's decision on the abstract.

If a selected author cannot attend, the presenting author should assign a replacement.

The following presentation formats are applicable for EACR-19:

- 1. Oral presentation: the abstract is selected for oral presentation in one of the two Presidential Sessions.
- 2. Poster: abstracts that have been selected for presentation in poster format. Posters are grouped by topic and are displayed on an allocated day of the conference.

Please note that if the abstract is accepted, the presenting author is entitled to register at the early rate. This special registration will be open for ONE WEEK only. The presenting authors will be notified in May 2006 about the deadline for this registration.

#### General instructions for abstract submission

Abstracts must be submitted on-line, from 6 January 2006 to 10 March 2006, via the FECS website: www.fecs.be Please follow the instructions on the screen.

#### Please note:

- 1. As a confirmation of your submission, a message will appear on the screen informing you the abstract has been successfully submitted to our database
- 2. The presenting author only will receive confirmation by e-mail from the EACR-19 secretariat within 48 hours of submission. This confirmation of abstract submission does not mean your abstract has been selected for presentation.
- 3. If you do not receive any confirmation, please contact the secretariat (Pat@fecs.be) within one week following the submission of the abstract and no later than 17 March 2006.

For questions regarding the on-line submission process, please e-mail: Pat@fecs.be

#### Warning

Only electronic abstracts can be accepted. Abstracts by e-mail or paper submissions will not be accepted.

## **Abstract topics**

Please select only ONE topic (1 to 11) that refers to the main subject of the abstract.

1	Signalling pathways	6	Clinical research
	Oncogenes and tumour		Organ site-specific investigations: preclinical,
	suppressor genes		diagnosis, treatment
	Receptors and signal transduction		Molecular biology in the clinic
	Gene expression,	7	Experimental/molecular therapeutics,
	transcriptional regulation		pharmacogenomics
	Cell cycle		Drug discovery/drug design
	Senescence		Novel targets, delivery systems
2	Oncogenomics		Mechanisms of drug action,
	Genomic alterations in cancer		drug profiling
	Functional genomics		Drug resistance
3	Cell and tumour biology		Novel approaches to
,	Cell proliferation		diagnosis of cancer
	Cell death		New therapies
	Tumour progression:	8	Radiobiology/radiation oncology
	invasion and metastasis		Tumour cell sensitization
	Tumour angiogenesis		to radiotherapy
	Tumour immunology, inflammation		Radiation-activated signaling pathways
	and tumour development		Cell cycle and apoptosis in
	Aging and cancer, telomerase		radiation responses
	Animal models of cancer		Radiation oncology;
4	Carcinogenesis		preclinical and clinical
	Mutagenesis, carcinogen metabolism	9	Prevention and survivorship research
	Promotion and progression		Preclinical prevention studies,
	DNA damage and repair		markers and prevention
	Viral oncogenesis		Clinical prevention studies
			Survivorship research
5	General, molecular and		Vaccination against cancer
	genetic epidemiology	10	Systems biology
	Risk factors		Proteomics/mass spectrometry
	Biomarkers		Computational models
	Risk assessment		of biological systems
	Susceptibility genes		Integrated biology
	Genotype/phenotype correlations	11	Other
	Genetic polymorphisms and cancer susceptibility	<b>-</b> ''	Other
	and cancer susceptibility		Other

#### REGISTRATION

#### **Pre-registration**

Deadline early registration (receipt of payment): 3 February 2006. Deadline late registration (receipt of payment; closure pre-registration): 16 June 2006

Corresponding payments should be received before the indicated deadline. Pre-registration closes on 16 June 2006. After this date, registration will be accepted on-site in Budapest only.

Please register on-line: www.fecs.be

If you do not have on-line access, please complete the enclosed registration form and return it by fax to +32 (0)2 775 02 00.

#### **Payment**

Full payment in Euro (EUR) should be received before the corresponding deadline.

Payment guaranteed by credit card (Eurocard/Mastercard, Visa, Diners Club or American Express) is preferred. Please indicate the owner's name as shown on the card

It is possible to pay by direct transfer into the EACR-19 account, IBAN BE 15 4254 0400 8130 with KBC Bank, SWIFT Code / BIC KRED BE BB, Chaussée de Wavre 1662, B-1160 Brussels.

For ease of processing, please indicate clearly the participant's name, address and the purpose for which the payment is made in all remittances.

## **On-site registrations**

Registrations on-site can be paid either by:

- Credit card (Visa, American Express, Diners Club or Eurocard/ Mastercard)
- In cash (payment only in Euro)

## **Confirmation of registration**

A combined confirmation of registration/acknowledgement of payment will be sent to each registrant on receipt of payment. No confirmation will be sent before payment is received.

## Replacement of registration

Participants who have pre-registered but are unable to attend can be replaced by another participant subject to a replacement fee of 30 EUR.

## **Cancellation of registration**

In case of cancellation without replacement, the fee minus handling charges of 75 EUR will be refunded provided a written request is received by the EACR-19 Conference Secretariat before 16 June 2006.

No refunds can be made if notice of cancellation is received after this date

#### **Group registration**

For group registrations of a minimum of 10 participants, from pharmaceutical and product companies, medical publishers and travel agents, please contact the EACR-19 Secretariat:

Ms. Riitta Kettunen

Telephone: +32 (0)2 775 02 01 Fax: +32 (0)2 775 02 00 E-mail: Riitta@fecs.be

## **Registration fees**

	Early rate	Late rate	Desk rate	Day rate
	Payment received before 3 February 2006	Payment received before 16 June 2006	On-site only	On-site only
Members EACR	275 EUR	330 EUR	400 EUR	175 EUR
Non-members	350 EUR	430 EUR	500 EUR	175 EUR
<b>Student</b> Members EACR*	115 EUR	115 EUR	115 EUR	175 EUR
Students Non-members*	175 EUR	175 EUR	175 EUR	175 EUR

<sup>\*</sup>Under 30 years. Please send a letter from your head of department to confirm your student status.

## **EACR 19 MEETING BURSARIES**

#### (For EACR members only)

- Meeting Bursaries will be awarded to assist members of the EACR to attend EACR-19. Preference will be given to those actively participating in the meeting.
- The scheme is designed to assist younger members of the Association particularly post graduate students and members less than 35 years old, who otherwise would have major difficulties in securing alternative funding.
- The value of each award may be up to 1 000 EUR. This grant will be used to assist with the cost of registration fee, travel and accommodation.

## Applications should be accompanied by:

- a. Copy of meeting abstract submitted to the conference
- b. Letter of support from the applicant's sponsor
- c. One page CV
- d. Short publication list (if available).

Application forms will be available in November 2005 from the EACR Secretariat

Tel: +44 115 9515114 Fax: +44 115 9515115

E-mail: kathryn.wass@nottingham.ac.uk

## **A**CCOMMODATION

## The deadline for hotel reservation is 19 May 2006

Connections 2000 Ltd. is the official accommodation agent for EACR-19.

Rooms have been reserved in different hotel categories. Please complete the detachable "Hotel accommodation form" and return it to:

#### Connections 2000 Ltd.

H-1016 Budapest Hegyalja út 18. Telephone: +36 (0)1 209 0380 Fax: +36 (0)1 209 9334

E-mail: eacr19@conn2000.hu

For on-line bookings, please go to www.fecs.be

#### **Cancellation policy**

Until 31 March 2006	Full refund of hotel deposit
From 1 April to 1 May 2006	50% of hotel deposit reimbursed
From 2 May to 1 June 2006	25 % of hotel deposit reimbursed
As from 2 June 2006	No refund of the hotel deposit


## "No shows" will be charged as follows:

One night deposit for: Novotel Budapest Congress Hotel Congress Hotel Flamenco Mercure Buda Budapest Mercure Duna Budapest Hotel Bara

All booked nights for Intercontinental Budapest

## **Hotel list**

	Hotel	Category	Single (in EUR)	Double (in EUR)
1	Intercontinental Budapest	****	135	155
2	Mercure Buda Budapest	****	90	105
3	Novotel Budapest Congress	****	90	105
4	Congress Park Hotel Flamenco	****	85	90
5	Mercure Duna Budapest	***	75	85
6	Hotel Bara	***	50	65



## Public transport connections from the congress hotels to Novotel Budapest Congress Centre

#### **Hotel Bara**

5 minutes walking distance

#### **Mercure Buda Budapest**

Take tram n° 61 from the station "Déli-pályaudvar" (South railway station) until the station "Csörsz utca" (in front of the Novotel Budapest Congress on the Alkotás street).

#### **Mercure Budapest Duna**

Take tram n° 6 until the endstation "Móricz Zsigmond körtér", take tram n° 61 from the same square until station "BAH-csomópont-Alkotás utca" (in front of Novotel Budapest Congress).

#### **Intercontinental Budapest**

The bus stop of bus n° 8 or n° 112 is at 5 minutes walking distance from the hotel and it takes approximately 10 minutes to the Congress Centre. It is the 4th stop which is in front of the Congress Centre.

## **Transport fares**

(1 EUR = 253 HUF exchange rate from May 2005)

Bus / Metro / Tram ticket	160 HUF (0,63 EUR) / way / person
Taxi from the airport to Pest side of the city:	3.500 HUF (13,83 EUR) /way
Taxi from the airport to Buda side of the city:	4.000 HUF (15,81 EUR) /way
Shuttle service (airport => city center)	2 300 HUF (9,09 EUR) / way / person

## EXHIBITION | SATELLITE SYMPOSIA | WORKSHOPS

Companies, publishers and organisations that would like to participate in this conference and help us to support cancer research can download the "Invitation to the industry" brochure from the website: www.fecs.be or contact Ms. Mieke Akkers, telephone: +32 (0)2 775 02 47, e-mail: Mieke@fecs.be.

#### GENERAL INFORMATION

#### Accreditation

Continuing Medical Education (CME) accreditation has been requested from the Accreditation Council for Oncology in Europe (ACOE).

#### **Climate**

The average daytime temperature in Budapest in July is 25°C. **Currency** 

The official currency is the Hungarian Forint (HUF). Most foreign currencies can be converted in banks, hotels or exchange offices. International credit cards are accepted in most hotels, restaurants and shops.

1 EUR = 253 HUF (May 2005)

#### Insurance

The organiser does not accept responsibility for individual medical, travel or personal insurance. Participants are advised to take out their own personal insurance policies.

## Language

The official language of the conference is English. No simultaneous translation will be provided.

## Passport and visa information

A valid passport and/or identity card is required for all participants. Visas may be required for some countries. For specific information, please contact the nearest Hungarian embassy at least six weeks before your departure to Hungary.

## **S**OCIAL PROGRAMME

#### Opening ceremony – Saturday 1 July at 13.00

The official Opening ceremony, to which all participants are kindly invited, will be held in the Patria Auditorium of Novotel Budapest Congress Centre

## Welcome reception - Saturday 1 July at 17.00

The Welcome reception will be held in the foyers of the Congress Centre.

#### Conference dinner – Monday 3 July at 20.00

The Conference dinner will be held in one of the most elegant venues in the city of Budapest. The dinner will be a feast of the finest Hungarian food served in baroque style. The guests will be serenaded by traditional music performed by a local gypsy band.

Dress code: casual

Price: 50 FUR - Students: 30 FUR

There is a limited capacity. Advance booking is strongly recommended. Tickets will be sold on a first-come, first-served basis. Please note that there will be no entrance without a ticket and the tickets are non-refundable

## **Guided tours in Budapest and Hungary**

Please contact Connections 2000 Ltd.

#### Connections 2000 Ltd.

H-1016 Budapest Hegyalja út 18. Telephone: +36 (0)1 209 0380

Fax: +36 (0)1 209 9334 E-mail: eacr19@conn2000.hu info@conn2000 hu





